Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Abstract 4299: A lineage-specific role of oncogenic protein kinase Cι in lung adenocarcinoma
Nguyen, Duy T. , Yin, Ning , Weems, Capella, Jamieson, Lee, Murray, Nicole R., Fields, Alan P. , Yin, Ning, Meneses, Kayleah M.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 4299-4299

10.1158/1538-7445.am2024-4299 Get It

Abstract Lung adenocarcinoma (LUAD), the most prevalent subtype of lung cancer, can arise from two different cell populations: alveolar type 2 (AT2) cells and bronchiolar club cells. By utilizing genomic data from the cancer genome atlas program, human LUAD cell lines, and the well-characterized LSL-KrasG12D/Trp53-/- (KP) mouse model, we demonstrated that tumors arising from club cells are much more aggressive and follow a different trajectory of tumorigenesis when compared to those arising from AT2 cells. Intriguingly, our data strongly suggest that expression and signaling activity of protein kinase C iota (PKCι) can profoundly affect the cell of origin and oncogenic signaling pathways employed by resultant tumors. Specifically, KP-mediated transformation of club cells appears to be dependent on PKCι-ELF3-NOTCH3 and PKCι-YAP1 signaling axes, while AT2 cell malignancy is dependent on the PKCι-independent WNT signaling. In addition, club-cell-origin tumors exhibit an enrichment of cancer stem cells and increased infiltration of immunosuppressive myeloid cells in comparison to AT2-cell-origin tumors. This results in accelerated progression and increased likelihood of metastasis by LUAD tumors that originate from club cells. Taken together, our results indicate that PKCι expression and signaling activity can profoundly influence the cells of origin, tumor trajectories, and therapeutic vulnerabilities of LUAD tumors. Citation Format: Duy T. Nguyen, Ning Yin, Capella R. Weems, Lee Jamieson, Kayleah Meneses, Yi Liu, Nicole R. Murray, Alan P. Fields. A lineage-specific role of oncogenic protein kinase Cι in lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4299.
Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease
Nguyen, Hai V. , Mital, Shweta , Knopman, David S. , Alexander, G. Caleb, Knopman, David S.

Mayo Clinic

Neurology | March 14, 2024 | Volume: 102 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000209218 | PMID 38484190 Get It

Atypical Bilateral Idiopathic Inflammatory Cavernous Sinus Syndrome Responsive to Cyclophosphamide
Nathoo, Nabeela , Chodnicki, Kevin D. , Krecke, Karl N. , Nguyen, Aivi T. , Toledano, Michel , Kantarci, Orhun H. , Nguyen, Aivi T , Nathoo, Nabeela , Gompel, Jamie J. Van

Mayo Clinic

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques | March 5, 2024 | Volume: 52 | Issue: 1 | Pages: 159-161

10.1017/cjn.2024.29 | PMID 38443750 Get It

Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion”
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Kwon-Chung, Kyung J , Nguyen, M Hong , Palavecino, Elizabeth , Pancholi, Preeti , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Roilides, Emmanuel , Wengenack, Nancy L , Wiederhold, Nathan , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Ahmed, Sarah A , Luethy, Paul , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Gräser, Yvonne , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Leal, Sixto M. , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Wiederhold, Nathan P. , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | March 5, 2024 | Volume: 62 | Issue: 4 | Pages: No page available

10.1128/jcm.01625-23 | PMID 38441056 Get It

(253) Use of Online Pharmacy Tools May Lead to Significantly Reduced National Expenditures on Vaginal Estrogen
Hammad, Muhammed , Loeb, C , Miller, Julie Ann, Yafi, FA, Hammad, Muhammed A M , Nguyen, M, Azad, Babak Kazemzadeh

Mayo Clinic

The Journal of Sexual Medicine | March 5, 2024 | Volume: 21 | Issue: Supplement_2 | Pages: No page available

10.1093/jsxmed/qdae002.219 Get It

Abstract Introduction High medication costs for vaginal estrogen may create a barrier for patients seeking treatment for numerous urinary and vaginal symptoms and lead to poor medication adherence. The Mark Cuban Cost Plus Drug Company (CPD) and GoodRx tools offer patients a method to purchase prescription medications at a discount, which may lead to improved medication adherence and decreased national expenditures on such medications. Objective To compare the pricing of vaginal estrogen as advertised by retail pharmacies, Medicare, and discount listings through CPD and GoodRx. Methods A review of publicly available data from CPD and GoodRx was performed to obtain listed retail and discounted prices for Estrace (topical), Vagifem (tablet), and Premarin (topical). GoodRx prices were obtained using prices from Costco, CVS, Walgreens, and Walmart pharmacies in the most from populous zip code from each of the 3 most populous U.S. states: California, New York, and Texas. Prices were adjusted to account for dosage and prescribed quantity to estimate an average cost per dosage unit ($/adu). The Medicare Part D Drug Spending and Utilization data from 2021 were used to report the average spending per dosage unit and total expenditure for each of the listed medications. These data were compared to create an estimate of average national savings after use of CPD and/or GoodRx. Results Average spending per dosage unit for Estrace, Vagifem, and Premarin was lesser when discount tools were used (0.50 $/adu, 3.75 $/adu, and 4.30 $/adu respectively), compared to Medicare pricing (6.14 $/adu, 20.95 $/adu, and 10.10 $/adu respectively) or retail pricing (3.14 $/adu, 10.19 $/adu, and 5.43 $/adu respectively). When adjusted for total dosage units, use of CPD over Medicare pricing for the three medications would result in a combined annual national saving of $64.2M. Use of either CPD or GoodRx compared to retail pricing would similarly result in a combined annual national saving of $39.2M. Conclusions The utilization of CPD and GoodRx in the prescription of vaginal estrogen led to a substantial national average cost savings when compared to retail and Medicare pricing. CPD and GoodRx may offer a way to decrease the cost burden for patients seeking treatment for urinary and vaginal symptoms and significantly reduce national expenditures on medications. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: The utilization of CPD and GoodRx in the prescription of vaginal estrogen led to a substantial national average cost savings when compared to retail and Medicare pricing. CPD and GoodRx may offer a way to decrease the cost burden for patients seeking treatment for urinary and vaginal symptoms and significantly reduce national expenditures on medications.
A small molecule MST1/2 inhibitor accelerates murine liver regeneration with improved survival in models of steatohepatitis
Watkins, Ryan , Gamo, Ana M. , Choi, Seung Hyuk , Kumar, Manoj , Buckarma, EeeLN H. , McCabe, Chantal E. , Tomlinson, Jennifer L. , Pereya, David, Lupše, Blaž , Geravandi, Shirin , Werneburg, Nathan W., Zhu, Siying , Li, Sijia, Yu, Shan , Surakattula, Murali, Baguley, Tyler D., Ardestani, Amin , Roland, Jason, Petrassi, Mike, Rogers, Nikki Lynn, Chatterjee, Arnab K. , Tremblay, Matthew S. , Smoot, Rory L. , Buckarma, EeeLN , McCabe, Chantal , Tomlinson, Jennifer , Wang, Chen , Starlinger, Patrick , Li, Sijia , Ardestani, Amin , Maedler, Kathrin , Joseph, Sean , Rogers, Nikki , Gores, Gregory J. , Chatterjee, Arnab , Shen, Weijun , Smoot, Rory L , Wang, Chen , Starlinger, Patrick , Nguyen-Tran, Vân T. B. , Gores, Gregory J.

Mayo Clinic

PNAS Nexus | March 1, 2024 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/pnasnexus/pgae096 | PMID 38528952 Get It

Abstract Dysfunctional liver regeneration following surgical resection remains a major cause of postoperative mortality and has no therapeutic options. Without targeted therapies, the current treatment paradigm relies on supportive therapy until homeostasis can be achieved. Pharmacologic acceleration of regeneration represents an alternative therapeutic avenue. Therefore, we aimed to generate a small molecule inhibitor that could accelerate liver regeneration with an emphasis on diseased models, which represent a significant portion of patients who require surgical resection and are often not studied. Utilizing a clinically approved small molecule inhibitor as a parent compound, standard medicinal chemistry approaches were utilized to generate a small molecule inhibitor targeting serine/threonine kinase 4/3 (MST1/2) with reduced off-target effects. This compound, mCLC846, was then applied to preclinical models of murine partial hepatectomy, which included models of diet-induced metabolic dysfunction-associated steatohepatitis (MASH). mCLC846 demonstrated on target inhibition of MST1/2 and reduced epidermal growth factor receptor inhibition. The inhibitory effects resulted in restored pancreatic beta-cell function and survival under diabetogenic conditions. Liver-specific cell-line exposure resulted in Yes-associated protein activation. Oral delivery of mCLC846 perioperatively resulted in accelerated murine liver regeneration and improved survival in diet-induced MASH models. Bulk transcriptional analysis of regenerating liver remnants suggested that mCLC846 enhanced the normal regenerative pathways and induced them following liver resection. Overall, pharmacological acceleration of liver regeneration with mCLC846 was feasible, had an acceptable therapeutic index, and provided a survival benefit in models of diet-induced MASH.
Polycyclic Aromatic Hydrocarbons and Pancreatic Cancer: An Analysis of the Blood Biomarker, r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthrene and Selected Metabolism Gene SNPs
Nguyen, Sierra, Oberg, Ann L. , Petersen, Gloria M. , Carmella, Steven G. , Jansen, Rick J. , Oberg, Ann L , Jansen, Rick J , Carlson, Heather, Yoder, Andrea R. , Bamlet, William R. , Hecht, Stephen S.

Mayo Clinic

Nutrients | February 29, 2024 | Volume: 16 | Issue: 5 | Pages: 688

10.3390/nu16050688 | PMID 38474816 Get It

Exposure to polycyclic aromatic hydrocarbons (PAHs), byproducts of incomplete combustion, and their effects on the development of cancer are still being evaluated. Recent studies have analyzed the relationship between PAHs and tobacco or dietary intake in the form of processed foods and smoked/well-done meats. This study aims to assess the association of a blood biomarker and metabolite of PAHs, r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4-tetrahydrophenanthrene (PheT), dietary intake, selected metabolism SNPs, and pancreatic cancer. Demographics, food-frequency data, SNPs, treatment history, and levels of PheT in plasma were determined from 400 participants (202 cases and 198 controls) and evaluated based on pancreatic adenocarcinoma diagnosis. Demographic and dietary variables were selected based on previously published literature indicating association with pancreatic cancer. A multiple regression model combined the significant demographic and food items with SNPs. Final multivariate logistic regression significant factors (p-value < 0.05) associated with pancreatic cancer included: Type 2 Diabetes [OR = 6.26 (95% CI = 2.83, 14.46)], PheT [1.03 (1.02, 1.05)], very well-done red meat [0.90 (0.83, 0.96)], fruit/vegetable servings [1.35 (1.06, 1.73)], recessive (rs12203582) [4.11 (1.77, 9.91)], recessive (rs56679) [0.2 (0.06, 0.85)], overdominant (rs3784605) [3.14 (1.69, 6.01)], and overdominant (rs721430) [0.39 (0.19, 0.76)]. Of note, by design, the level of smoking did not differ between our cases and controls. This study does not provide strong evidence that PheT is a biomarker of pancreatic cancer susceptibility independent of dietary intake and select metabolism SNPs among a nonsmoking population.
Incidence and clinical outcomes of perforations during mechanical thrombectomy for medium vessel occlusion in acute ischemic stroke: A retrospective, multicenter, and multinational study
Musmar, Basel , Salim, Hamza , Kobeissi, Hassan , Shaikh, Hamza , Khalife, Jane , Abdalkader, Mohamad , Klein, Piers , Heit, Jeremy J. , Regenhardt, Robert W. , Cancelliere, Nicole M , Amllay, Abdelaziz , Dusart, Anne , Bellante, Flavio, Rouchaud, Aymeric , Puri, Ajit S , Dyzmann, Christian , Kan, Peter , Colasurdo, Marco , Berge, Jérôme , Barreau, Xavier , Nedelcu, Simona , Henninger, Nils , Marotta, Thomas R. , Stapleton, Christopher J. , Rabinov, James D. , Dofuku, Shogo , Tan, Benjamin Yong‐Qiang , Salazar‐Marioni, Sergio , Capirossi, Carolina , Chervak, Lina , Adeeb, Nimer , Tjoumakaris, Stavropoula , Khandelwal, Priyank , Biswas, Arundhati , Clarençon, Frédéric , Elhorany, Mahmoud , Premat, Kévin , Valente, Iacopo , Filipe, João Pedro , Varela, Ricardo , Quintero‐Consuegra, Miguel , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Yedavalli, Vivek , Aziz, Yasmin , Stracke, Christian Paul , Kadirvel, Ramanathan , Hsieh, Cheng‐Yang , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Musmar, Basel , Salim, Hamza , Kobeissi, Hassan , Klein, Piers , Nguyen, Thanh N , Regenhardt, Robert W , Bellante, Flavio , Forestier, Géraud , Marnat, Gaultier , Ota, Takahiro , Dofuku, Shogo , Yeo, Leonard Ll , Salazar-Marioni, Sergio , Jabbour, Pascal , Gonzalez, Nestor R , Möhlenbruch, Markus A , Jesser, Jessica , Aziz, Yasmin , Alexandru Radu, Răzvan , Faizy, Tobias D , Fahed, Robert , Liebeskind, David S. , Heit, Jeremy J , Yedavalli, Vivek S , Cancelliere, Nicole M , Rouchaud, Aymeric , Colasurdo, Marco , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Dmytriw, Adam A. , Ghozy, Sherief , Siegler, James E. , Nguyen, Thanh N. , Bernstock, Joshua D. , Naamani, Kareem El , Meyer, Lukas , Forestier, Géraud , Saleme, Suzana , Mounayer, Charbel , Fiehler, Jens , Kühn, Anna Luisa , Sibon, Igor , Gopinathan, Anil , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Renieri, Leonardo , Mowla, Ashkan , Vagal, Achala , Cuellar, Hugo , Jabbour, Pascal , Khandelwal, Priyank , Pedicelli, Alessandro , Schiphorst, Adrien ter , Harker, Pablo , Gory, Benjamin , Hecker, Constantin , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Thomas, Ajith J , Radu, Răzvan Alexandru , Fahed, Robert , Weyland, Charlotte S. , Mendes Pereira, Vitor

Mayo Clinic

European Stroke Journal | February 27, 2024 | Volume: 9 | Issue: 2 | Pages: 328-337

10.1177/23969873231219412 | PMID 38409796 Get It

Abstract Background: Mechanical thrombectomy (MT) has revolutionized the treatment of acute ischemic stroke (AIS) due to large vessel occlusion (LVO), but its efficacy and safety in medium vessel occlusion (MeVO) remain less explored. This multicenter, retrospective study aims to investigate the incidence and clinical outcomes of vessel perforations (confirmed by extravasation during an angiographic series) during MT for AIS caused by MeVO. Methods: Data were collected from 37 academic centers across North America, Asia, and Europe between September 2017 and July 2021. A total of 1373 AIS patients with MeVO underwent MT. Baseline characteristics, procedural details, and clinical outcomes were analyzed. Results: The incidence of vessel perforation was 4.8% (66/1373). Notably, our analysis indicates variations in perforation rates across different arterial segments: 8.9% in M3 segments, 4.3% in M2 segments, and 8.3% in A2 segments (p = 0.612). Patients with perforation had significantly worse outcomes, with lower rates of favorable angiographic outcomes (TICI 2c-3: 23% vs 58.9%, p &lt; 0.001; TICI 2b-3: 56.5% vs 88.3%, p &lt; 0.001). Functional outcomes were also worse in the perforation group (mRS 0–1 at 3 months: 22.7% vs 36.6%, p = 0.031; mRS 0–2 at 3 months: 28.8% vs 53.9%, p &lt; 0.001). Mortality was higher in the perforation group (30.3% vs 16.8%, p = 0.008). Conclusion: This study reveals that while the occurrence of vessel perforation in MT for AIS due to MeVO is relatively rare, it is associated with poor functional outcomes and higher mortality. The findings highlight the need for increased caution and specialized training in performing MT for MeVO. Further prospective research is required for risk mitigation strategies.
The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Luque, Laura F. Mendez , Avelar‐Barragan, Julio , Nguyen, Hellen , Nguyen, Jenny , Soyfer, Eli M. , Liu, Jiarui , Chen, Jane H. , Mehrotra, Nitya , Huang, Xin , Kosiorek, Heidi , Dueck, Amylou C. , Heide, Elena , Lem, Melinda , Alaoui, Kenza El , Mas, Eduard , Scherber, Robyn M. , Whiteson, Katrine , Dueck, A. C. , Mendez Luque, Laura F , Kosiorek, Heidi E , Himstead, Alexander , Heide, Elena , Lem, Melinda , El Alaoui, Kenza , Mas, Eduard , Scherber, Robyn M , Mesa, Ruben , Whiteson, Katrine L , Odegaard, Andrew , Fleischman, Angela G , Mesa, Ruben A. , Fleischman, Angela G.

Mayo Clinic

Cancer Research Communications | February 23, 2024 | Volume: 4 | Issue: 3 | Pages: 660-670

10.1158/2767-9764.crc-23-0380 | PMID 38391189 Get It

Abstract Purpose: Chronic inflammation is integral to myeloproliferative neoplasm (MPN) pathogenesis. JAK inhibitors reduce cytokine levels, but not without significant side effects. Nutrition is a low-risk approach to reduce inflammation and ameliorate symptoms in MPN. We performed a randomized, parallel-arm study to determine the feasibility of an education-focused Mediterranean diet intervention among patients with MPN. Experimental Design: We randomly assigned patients with MPN to either a Mediterranean diet or standard U.S. Dietary Guidelines for Americans (USDA). Groups received equal but separate education with registered dietician counseling and written dietary resources. Patients were prospectively followed for feasibility, adherence, and symptom burden assessments. Biological samples were collected at four timepoints during the 15-week study to explore changes in inflammatory biomarkers and gut microbiome. Results: The Mediterranean diet was as easy to follow for patients with MPN as the standard USDA diet. Approximately 80% of the patients in the Mediterranean diet group achieved a Mediterranean Diet Adherence Score of ≥8 throughout the entire active intervention period, whereas less than 50% of the USDA group achieved a score of ≥8 at any timepoint. Improvement in symptom burden was observed in both diet groups. No significant changes were observed in inflammatory cytokines. The diversity and composition of the gut microbiome remained stable throughout the duration of the intervention. Conclusions: With dietician counseling and written education, patients with MPN can adhere to a Mediterranean eating pattern. Diet interventions may be further developed as a component of MPN care, and potentially incorporated into the management of other hematologic conditions. Significance: Diet is a central tenant of management of chronic conditions characterized by subclinical inflammation, such as cardiovascular disease, but has not entered the treatment algorithm for clonal hematologic disorders. Here, we establish that a Mediterranean diet intervention is feasible in the MPN patient population and can improve symptom burden. These findings warrant large dietary interventions in patients with hematologic disorders to test the impact of diet on clinical outcomes.
Factors Affecting Selection of TraineE for Neurointervention (FASTEN)
Elfil, Mohamed , Ghozy, Sherief , Elmashad, Ahmed , Al‐Bayati, Alhamza R , Alaraj, Ali , Brook, Allan , Kam, Anthony W. , Waldau, Ben , Altschul, David , Parrella, David Turkel, Tóth, Gábor , Jindal, Gaurav , Shaikh, Hamza , Dolia, Jaydevsinh , Thomas, Justin, Kim, Louis J. , Harrigan, Mark R. , Kole, Max , Mokin, Max, Janjua, Nazli , Zaidat, Osama O. , Youssef, Patrick , Khandelwal, Priyank , Wang, Qingliang Tony, Szeder, Viktor , Tanweer, Omar , Jankowitz, Brian T. , Heit, Jeremy J. , Williamson, Richard , Kass‐Hout, Tareq , Crowley, R. Webster , El‐Ghanem, Mohammad , Kam, Anthony , Ghozy, Sherief , Siddiqui, Adnan H , Al-Bayati, Alhamza , Alaraj, Ali , Kam, Anthony W , Matouk, Charles , Schirmer, Clemens M , Altschul, David J , Shaikh, Hamza A , Amuluru, Krishna , Grandhi, Ramesh , Hanel, Ricardo A , Ortega-Gutierrez, Santiago , Nguyen, Thanh N , Szeder, Viktor , Heit, Jeremy J , Al-Mufti, Fawaz , Elfil, Mohamed , Dolia, Jaidevsinh , Morsi, Rami Z. , Siddiqui, Adnan H. , Chatterjee, Arindam R , Patsalides, Athos T , Prestigiacomo, Charles Joseph , Matouk, Charles , Schirmer, Clemens M. , Fifi, Johanna T , Fraser, Justin F , Kim, Louis J. , Amans, Matthew R. , Abraham, Michael G. , Jumaa, Mouhammad , Grandhi, Ramesh , Hanel, Ricardó A. , Kellogg, Ryan Thomson , Sheth, Sunil A , Nguyen, Thanh N. , Hu, Yin , Yoo, Albert J. , Al‐Mufti, Fawaz

Mayo Clinic

Interventional Neuroradiology | February 23, 2024 | Volume: 32 | Issue: 4 | Pages: 1253-1260

10.1177/15910199241232726 | PMID 38389309 Get It

Background and importance Neurointervention is a very competitive specialty in the United States due to the limited number of training spots and the larger pool of applicants. The training standards are continuously updated to ensure solid training experiences. Factors affecting candidate(s) selection have not been fully established yet. Our study aims to investigate the factors influencing the selection process. Methods A 52-question survey was distributed to 93 program directors (PDs). The survey consisted of six categories: (a) Program characteristics, (b) Candidate demographics, (c) Educational credentials, (d) Personal traits, (e) Research and extracurricular activities, and (f) Overall final set of characteristics. The response rate was 59.1%. As per the programs’ characteristics, neurosurgery was the most involved specialty in running the training programs (69%). Regarding demographics, the need for visa sponsorship held the greatest prominence with a mean score of 5.9 [standard deviation (SD) 2.9]. For the educational credentials, being a graduate from a neurosurgical residency and the institution where the candidate's residency training is/was scored the highest [5.4 (SD = 2.9), 5.4 (SD = 2.5), respectively]. Regarding the personal traits, assessment by faculty members achieved the highest score [8.9 (SD = 1)]. In terms of research/extracurricular activities, fluency in English had the highest score [7.2 (SD = 1.9)] followed by peer-reviewed/PubMed-indexed publications [6.4 (SD = 2.2)]. Conclusion Our survey investigated the factors influencing the final decision when choosing the future neurointerventional trainee, including demographic, educational, research, and extracurricular activities, which might serve as valuable guidance for both applicants and programs to refine the selection process.